Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pramipexole and the Risk of Serious Adverse Events
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Summary
This is a population-based cohort study assessing whether initiation of a higher dose of pramipexole (0.25 or 0.375 mg/day), compared with a lower dose (0.125 mg/day), in older adults with advanced chronic kidney disease (CKD) (an estimated glomerular filtration rate \[eGFR\] \<45 mL/min/1.73 m² but not receiving dialysis or having a history of kidney transplantation) is associated with a higher 30-day risk of a composite outcome of all-cause hospitalization or all-cause emergency visits, or all-cause mortality.
Official title: Assessing the 30-Day Risk of Adverse Outcomes With Pramipexole Use in Older Adults With Advanced Chronic Kidney Disease: A Population-Based Cohort Study Research Protocol
Key Details
Gender
All
Age Range
66 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1100
Start Date
2008-01-01
Completion Date
2028-12-31
Last Updated
2026-09-14
Healthy Volunteers
No
Interventions
Pramipexole
The primary exposure of interest will be oral pramipexole at a 0.125 mg/day. For the primary comparison, this dose has been selected to reduce the potential influence of indication bias.
Locations (1)
London Health Sciences Centre Research Institute
London, Ontario, Canada